From the experimental data, we concluded that the levels of CD63, CA125WGA, and CA15‐3WGA may be used to differentiate localized BrCa from healthy controls significantly better than the levels of conventional glycoprotein tumor markers CA125 and CA15‐3. This evidence concerns the gene MUC16 and invasive breast carcinoma.